Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate the safety and effectiveness of orally-administered pyridoxal isonicotinoyl hydrazone (PIH) for the chronic treatment of iron overload.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Western Reserve University
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Pyridoxal isonicotinoyl hydrazone

Criteria

Study 1: Approximately 12 to 18 adult men and non-pregnant women with iron-loading anemias in the United States and 12 to 18 similar patients in Thailand each year.

Study 2: Approximately 6 to 12 well-chelated patients with transfusion-dependence.